[1]
|
Atar, D., Birkeland, K.I. and Uhlig, T. (2010) “Treat to Target”: Moving Targets from Hypertension, Hyperlipidaemia and Diabetes to Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 69, 629-630.
https://doi.org/10.1136/ard.2010.128462
|
[2]
|
Wangnoo, S.K., et al. (2014) Treat-to-Target Trials in Diabetes. In-dian Journal of Endocrinology and Metabolism, 18, 166-174. https://doi.org/10.4103/2230-8210.129106
|
[3]
|
Aletaha, D., Alasti, F. and Smolen, J.S. (2016) Optimisation of a Treat-to-Target Approach in Rheumatoid Arthritis: Strategies for the 3-Month Time Point. Annals of the Rheumatic Dis-eases, 75, 1479-1485.
https://doi.org/10.1136/annrheumdis-2015-208324
|
[4]
|
Smolen, J.S., et al. (2017) EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2016 Update. Annals of the Rheumatic Diseases, 76, 960-977.
|
[5]
|
Dures, E., et al. (2020) Treat-to-Target in PsA: Methods and Necessity. RMD Open, 6, e001083.
https://doi.org/10.1136/rmdopen-2019-001083
|
[6]
|
Franklyn, K., Hoi, A., Nikpour, M. and Morand, E.F. (2014) The Need to Define Treatment Goals for Systemic Lupus Erythematosus. Nature Reviews Rheumatology, 10, 567-571. https://doi.org/10.1038/nrrheum.2014.118
|
[7]
|
Van Vollenhoven, R.F., et al. (2014) Treat-to-Target in Systemic Lupus Erythematosus: Recommendations from an International Task Force. Annals of the Rheumatic Diseases, 73, 958-967.
https://doi.org/10.1136/annrheumdis-2013-205139
|
[8]
|
Franklyn, K., et al. (2016) Definition and Initial Validation of a Lupus Low Disease Activity State (LLDAS). Annals of the Rheumatic Diseases, 75, 1615-1621. https://doi.org/10.1136/annrheumdis-2015-207726
|
[9]
|
Van Vollenhoven, R., et al. (2017) A Framework for Re-mission in SLE: Consensus Findings from a Large International Task Force on Definitions of Remission in SLE (DORIS). Annals of the Rheumatic Diseases, 76, 554-561.
|
[10]
|
Fanouriakis, A., et al. (2019) 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 78, 736-745. https://doi.org/10.1136/annrheumdis-2019-215089
|
[11]
|
Hao, Y., et al. (2021) Determinants and Pro-tective Associations of the Lupus Low Disease Activity State in a Prospective Chinese Cohort. Clinical Rheumatology, 41, 357-366. https://doi.org/10.1007/s10067-021-05940-z
|
[12]
|
Tsang, A.S.M.W. and Bultink, I.E. (2015) System-ic Lupus Erythematosus: Review of Synthetic Drugs. Expert Opinion on Pharmacotherapy, 16, 2793-2806. https://doi.org/10.1517/14656566.2015.1101448
|
[13]
|
Bruce, I.N., et al. (2015) Factors Associated with Damage Accrual in Patients with Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 74, 1706-1713.
|
[14]
|
Gatto, M., Zen, M., Iacca-rino, L. and Doria, A. (2019) New Therapeutic Strategies in Systemic Lupus Erythematosus Management. Nature Re-views Rheumatology, 15, 30-48. https://doi.org/10.1038/s41584-018-0133-2
|
[15]
|
Golder, V., et al. (2017) Associ-ation of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life in a Multinational Prospec-tive Study. Arthritis Research & Therapy, 19, Article No. 62.
https://doi.org/10.1186/s13075-017-1256-6
|
[16]
|
Golder, V., et al. (2016) Frequency and Predictors of the Lupus Low Disease Activity State in a Multi-National and Multi-Ethnic Cohort. Arthritis Research & Therapy, 18, Article No. 260. https://doi.org/10.1186/s13075-016-1163-2
|
[17]
|
Babaoglu, H., Li, J., Goldman, D., Magder, L.S. and Petri, M. (2020) Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. Arthritis Care & Research, 72, 225-232.
https://doi.org/10.1002/acr.24063
|
[18]
|
Mucke, J., Dusing, C., Klose, N., Schneider, M. and Chehab, G. (2021) Remission in SLE—Do DORIS Criteria Match the Treating Physician’s Judgment? A Cross Sectional Study to Assess Reasons for Discordance. Rheumatology, 60, 4298-4305. https://doi.org/10.1093/rheumatology/keab005
|
[19]
|
Golder, V., et al. (2019) Evaluation of Remission Definitions for Systemic Lupus Erythematosus: A Prospective Cohort Study. The Lancet Rheumatology, 1, e103-e110. https://doi.org/10.1016/S2665-9913(19)30048-7
|
[20]
|
Ruiz-Irastorza, G., Danza, A. and Khamashta, M. (2012) Glucocorticoid Use and Abuse in SLE. Rheumatology (UK), 51, 1145-1153. https://doi.org/10.1093/rheumatology/ker410
|
[21]
|
Miloslavsky, E.M., Naden, R.P., Bijlsma, J.W.J., Brogan, P.A., Brown, E.S., Brunetta, P., et al. (2017) Development of a Glucocorticoid Toxicity Index (GTI) Using Multicriteria Deci-sion Analysis. Annals of the Rheumatic Diseases, 76, 543-546. https://doi.org/10.1136/annrheumdis-2016-210002
|
[22]
|
Al Sawah, S., Zhang, X., Zhu, B., Magder, L.S., Foster, S.A., Iikuni, N., et al. (2015) Effect of Corti-Costeroid Use by Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—The Hopkins Lupus Cohort. Lupus Science & Medicine, 2, e000066. https://doi.org/10.1136/lupus-2014-000066
|
[23]
|
Apostolopoulos, D., Kandane-Rathnayake, R., Raghunath, S., Hoi, A,. Nikpour, M. and Morand, E.F. (2016) Independent Association of Glucocorticoids with Damage Accrual in SLE. Lupus Science & Medicine, 3, e000157.
https://doi.org/10.1136/lupus-2016-000157
|
[24]
|
Ruiz-Arruza, I., Barbosa, C., Ugarte, A. and Ruiz-Irastorza, G. (2015) Comparison of High versus Low-Medium Prednisone Doses for the Treatment of Systemic Lupus Erythematosus Patients with High Activity at Diagnosis. Autoimmunity Reviews, 14, 875-879. https://doi.org/10.1016/j.autrev.2015.05.011
|
[25]
|
Wallace, D.J., Gudsoorkar, V.S., Weisman, M.H. and Venuturu-palli, S.R. (2012) New Insights into Mechanisms of Therapeutic Effects of Antimalarial Agents in SLE. Nature Reviews Rheumatology, 8, 522-533.
https://doi.org/10.1038/nrrheum.2012.106
|
[26]
|
Marmor, M.F., Kellner, U., Lai, T.Y.Y., Melles, R.B. and Mieler, W.F. (2016) Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology, 123, 1386-1394.
https://doi.org/10.1016/j.ophtha.2016.01.058
|